Deena Kuruvilla, AHS 2021: Phase 3 TEAM Results

touchNEUROLOGY had the pleasure to meet with Deena Kuruvilla (Westport Headache Institute, Westport, CT, USA) to discuss the phase 3 TEAM results investigating the Cefaly device as a non-pharmacological option for the prevention and acute treatment of migraine. The abstract ‘A Phase 3 randomized, double-blind, sham-controlled Trial of e-TNS for the Acute treatment of Migraine […]

Jessica Ailani, AHS 2021: RELIEF Study – Rapid Resolution of Migraine Symptoms After Initiating Eptinezumab

It was a great pleasure to meet with Jessica Ailani (AHS Scientific Committee Member) (MedStar Georgetown Headache Center, Georgetown, WA, USA) to discuss the RELIEF study results. The abstract ‘Rapid Resolution of Migraine Symptoms After Initiating the Preventive Treatment Eptinezumab During a Migraine Attack’ was presented at the American Headache Society (AHS) Virtual Annual Scientific […]

Jessica Ailani, AHS 2021: Headache Disorders – What’s on the Horizon for 2021?

touchNEUROLOGY met with Jessica Ailani (AHS Scientific Committee Member) (MedStar Georgetown Headache Center, Georgetown, WA, USA) to discuss the latest research and hot topics in headache/migraine medicine for 2021. Question: What are the hot topics and latest research you are looking forward to exploring in the headache/migraine field during 2021? Disclosures: Jessica Ailani receives honoraria […]

Jeffrey Guptill, AAN 2021: Vivacity-MG Study Results

We were delighted to meet with Jeffery Guptill (Duke University Medical Center, Durham, NC, USA) to discuss the Vivacity-MG study results (NCT03772587), investigating nipocalimab as a treatment option for Myasthenia Gravis. The abstract entitled: ‘Vivacity-MG: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Nipocalimab […]

Neuropathy Associated with Hereditary Transthyretin Amyloidosis—Diagnosis and Management

US Neurology. 2020;16(2):103–9 DOI: https://doi.org/10.17925/USN.2020.16.2.103

Hereditary transthyretin amyloidosis (hATTR) is a progressive life-threatening disease that typically presents as progressive sensorimotor polyneuropathy, restrictive cardiomyopathy, or a combination of both.1 Patients with hATTR-associated polyneuropathy (hATTR-PN) typically require assistance walking after 5–6 years, and die within 7–10 years from the onset of neuropathy.2 However, clinical manifestations of amyloidosis can affect other organs as well, including […]

Cenobamate for the Treatment of Focal Seizures

US Neurology. 2020;16(2):87–97 DOI: https://doi.org/10.17925/USN.2020.16.2.87

Epilepsy is a very common neurological disease, affecting more than 50 million people worldwide and 3.4 million people in the USA.1–3 Focal seizures, formerly partial-onset seizures, are the most common type, making up ≥60% of cases.4–6 Patients with epilepsy have an increased risk of morbidity and mortality, a decreased quality of life and are more likely […]

Olfaction in Parkinson’s Disease – A Clinical Approach

European Neurological Review. 2020;15(1):37–40 DOI: https://doi.org/10.17925/ENR.2020.15.1.37

Olfactory loss has been extensively studied in Parkinson’s disease (PD) and is now widely acknowledged as one of the major non-motor symptoms of the disease, which precedes the occurrence of clinical motor symptoms.1,2 It is found in around 90% of patients with PD,3–5 and has been considered as a supportive criterion in clinical PD diagnosis according to […]

Siponimod—A Selective Sphingosine-1-phosphate Modulator for Secondary Progressive Multiple Sclerosis

US Neurology. 2020;16(2):99–102 DOI: https://doi.org/10.17925/USN.2020.16.2.99

Multiple sclerosis (MS) is a chronic neuro-inflammatory condition estimated to affect over two million people worldwide. Several subtypes of MS have been described, and they are defined by their clinical phenotypes.1 The majority of patients initially exhibit relapsing remitting MS (RRMS), which is characterized by acute episodes of overt inflammation associated with abrupt clinical decline, most […]